Clinical trial
Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus…
NCT00198289 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00198289 |
|---|---|
| Title | Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs |
| Official title | A Phase IIa Dose Escalation Study to Assess Safety and Pharmacokinetics of Aurexis® in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Staphylococcus Aureus |
| Intervention type | Drug |
| Interventions | Aurexis® (tefibazumab) |
| Enrollment | 30 |
| Start date | Apr 1, 2005 |
| Completion | Jun 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 29, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: